Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Stockholm - Delayed Quote SEK

ODI Pharma AB (ODI.ST)

2.5800
0.0000
(0.00%)
At close: April 25 at 9:00:00 AM GMT+2
Loading Chart for ODI.ST
  • Previous Close 2.5800
  • Open 2.5800
  • Bid 2.1400 x --
  • Ask 2.5800 x --
  • Day's Range 2.5800 - 2.5800
  • 52 Week Range 1.5000 - 8.1500
  • Volume 77
  • Avg. Volume 2,074
  • Market Cap (intraday) 41.061M
  • Beta (5Y Monthly) 0.66
  • PE Ratio (TTM) --
  • EPS (TTM) -0.2400
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

ODI Pharma AB (publ), a pharmaceutical company, engages in the production and distribution of pharmaceutical cannabis and cosmetics products in Europe. It offers dried flowers; and cosmetics products under the Kandol brand. The company was founded in 2018 and is based in Stockholm, Sweden.

www.odipharma.com

1

Full Time Employees

June 30

Fiscal Year Ends

Recent News: ODI.ST

View More

Performance Overview: ODI.ST

Trailing total returns as of 4/25/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .

YTD Return

ODI.ST
16.22%
OMX Stockholm 30 Index (^OMX)
2.26%

1-Year Return

ODI.ST
54.74%
OMX Stockholm 30 Index (^OMX)
3.90%

3-Year Return

ODI.ST
53.60%
OMX Stockholm 30 Index (^OMX)
18.35%

5-Year Return

ODI.ST
51.69%
OMX Stockholm 30 Index (^OMX)
60.29%

Compare To: ODI.ST

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: ODI.ST

View More

Valuation Measures

Annual
As of 4/25/2025
  • Market Cap

    41.06M

  • Enterprise Value

    35.70M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.91

  • Price/Book (mrq)

    92.27

  • Enterprise Value/Revenue

    1.66

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -18.74%

  • Return on Assets (ttm)

    -26.68%

  • Return on Equity (ttm)

    -324.80%

  • Revenue (ttm)

    21.5M

  • Net Income Avi to Common (ttm)

    -4.03M

  • Diluted EPS (ttm)

    -0.2400

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    5.36M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -2.01M

Research Analysis: ODI.ST

View More

Company Insights: ODI.ST

Research Reports: ODI.ST

View More